(C) Severe active or active fistulising Crohn’s disease - historical notes
| Date | Note |
|---|---|
| 06/02/2025 | Addition of new amgevita formulations, ERWG Jan 24. |
| 22/10/2024 | Addition of Ustekinumab formulations, ERFC Oct 2024. |
| 09/07/2024 | Risankizumab SMC 2534. ERWG July 24. |
| 30/08/2023 | East Region Formulary content agreed - ERFC 09/08/2023. |